Market revenue in 2023 | USD 74.0 million |
Market revenue in 2030 | USD 104.1 million |
Growth rate | 5% (CAGR from 2023 to 2030) |
Largest segment | Phase iii |
Fastest growing segment | Phase I |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Phase I, Phase II, Phase III, Phase IV |
Key market players worldwide | Novartis AG ADR, Labcorp Holdings Inc, Medpace Holdings Inc, Charles River Laboratories International Inc, Icon PLC, GlaxoSmithKline Consumer Healthcare (GSK CH India), Aurora Innovation Inc Class A, Biogen Inc, IQVIA Holdings Inc, inVentiv Health |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to neurology clinical trials market will help companies and investors design strategic landscapes.
Phase iii was the largest segment with a revenue share of 47.03% in 2023. Horizon Databook has segmented the Brazil neurology clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
Brazil is a large country with a population of about 200 million people, making it the most populous country in Latin America. The country, which is divided into five regions, is the world's sixth-largest pharmaceutical market, with regulatory conformity to clinical trials enforced by experienced and skilled professionals.
It has a large treatment-naive population, which is rapidly aging & living much longer lives, which affects the epidemiologic profile and increases the prevalence of chronic diseases. The increasing number of clinical trials in the country & changing regulatory environment are anticipated to drive the market growth in Brazil.
Furthermore, research budget of the country has significantly improved. For instance, the federal research budget for Ministry of Science, Technology and Innovation accounted for USD 1.27 billion in 2022, which is 110% higher compared to the previous year The increase in the research budget of the country is likely to positively impact the market during the forecast period.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil neurology clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into Brazil neurology clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account